Oliver Glass, Daniel Liu, Elizabeth Bechard, Cynthia D. Guy, Jane Pendergast, Anna Mae Diehl, Manal F. Abdelmalek – 25 October 2021 – Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers and limitations to exercise in patients with NAFLD have not been fully identified.

Sebastian Niezen, Elliot B. Tapper, Hirsh Trivedi, Michelle Lai, Michael P. Curry, Kenneth J. Mukamal, Z. Gordon Jiang – 24 October 2021 – Cirrhosis, a rising cause of death in the United States, has an extended preclinical phase characterized by progressive liver fibrosis. Despite the developments in noninvasive fibrosis measurement, there is no recommended screening, in part due to an incomplete understanding of the disease epidemiology on a national scale. Herein, we aim to define the prevalence of liver fibrosis and compare strategies to identify the at‐risk population.

Qiaofeng Qian, Yang Li, Jiajun Fu, Dewen Leng, Zhe Dong, Jiajun Shi, Hongjie Shi, Dengwei Cao, Xu Cheng, Yufeng Hu, Qiujie Luo, Manli Hu, Yong Ran, Hao Tang, Hui Liu, Jinping Liu – 23 October 2021

Arshi Khanam, Lydia S. Y. Tang, Shyam Kottilil – 23 October 2021

Eléanor Luce, Clara Steichen, Mickaël Allouche, Antonietta Messina, Jean‐Marie Heslan, Thierry Lambert, Anne Weber, Tuan Huy Nguyen, Olivier Christophe, Anne Dubart‐Kupperschmitt – 22 October 2021

Juan‐Li Duan, Bai Ruan, Ping Song, Zhi‐Qiang Fang, Zhen‐Sheng Yue, Jing‐Jing Liu, Guo‐Rui Dou, Hua Han, Lin Wang – 22 October 2021

Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda, Masaki Mori – 22 October 2021 – We examined phosphorylated nuclear factor erythroid 2–related factor 2 (P‐NRF2) expression in surgically resected primary hepatocellular carcinoma (HCC) and investigated the association of P‐NRF2 expression with clinicopathological features and patient outcome.

Desley A. H. Neil, Marta Minervini, Maxwell L. Smith, Stefan G. Hubscher, Elizabeth M. Brunt, A. Jake Demetris – 21 October 2021

Tassos Grammatikopoulos, Nedim Hadzic, Pierre Foskett, Sandra Strautnieks, Marianne Samyn, Roshni Vara, Anil Dhawan, Jozef Hertecant, Fatma Al Jasmi, Obydur Rahman, University of Washington Center for Mendelian Genomics, Maesha Deheragoda, Laura N. Bull, Richard J Thompson – 21 October 2021 – Mutations in the transaldolase 1 (TALDO1) gene have been described in a limited number of cases. Several organs can be affected and clinical manifestations are variable, but often include liver dysfunction and/or hepatosplenomegaly.

Giuseppe Cullaro, Elizabeth C. Verna, Andres Duarte‐Rojo, Matthew R. Kappus, Daniel R. Ganger, Robert S. Rahimi, Brian Boyarsky, Dorry L. Segev, Mara McAdams‐DeMarco, Daniela P. Ladner, Michael L. Volk, Chi‐yuan Hsu, Jennifer C. Lai – 21 October 2021 – Acute kidney injury (AKI) and frailty are major drivers of outcomes among patients with cirrhosis. What is unknown is the impact of physical frailty on the development of AKI. We included adults with cirrhosis without hepatocellular carcinoma listed for liver transplantation at nine US centers (n = 1,033).